Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
14-3-3 zeta siRNA is a small interfering RNA (siRNA) designed to silence the expression of the *YWHAZ* gene, which encodes the 14-3-3 zeta protein. 14-3-3 zeta is a member of a highly conserved family of molecular chaperones that regulate various cellular processes, including signal transduction, cell cycle progression, and apoptosis. In many cancers, including head and neck squamous cell carcinoma (HNSCC), 14-3-3 zeta is overexpressed and correlates with poor prognosis and resistance to chemotherapy. By utilizing the RNA interference (RNAi) pathway, this siRNA mediates the degradation of 14-3-3 zeta mRNA, leading to reduced protein levels. Research has demonstrated that downregulation of 14-3-3 zeta sensitizes cancer cells to chemotherapeutic agents such as doxorubicin and cisplatin, inducing G2/M phase arrest and promoting apoptosis through the activation of caspase-3 and caspase-9.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 14-3-3 zeta siRNA.